Global survey reveals obesity hidden in normal BMI contributing to metabolic disorders
October 25, 2025 / abdominal obesity / normal BMI risks / cardiometabolic disease / global health study / metabolic syndrome
Over 20% of adults with normal BMI have abdominal obesity, significantly increasing risks of hypertension, diabetes, and dyslipidemia—highlighting the limitations of BMI alone in assessing cardiometabolic risk across global populations.
The 8-Year Study That Could Change How We Treat Obesity
October 24, 2025 / gut microbiome / obesity treatment / fecal transplant / metabolic health / adolescent obesity
An 8-year study shows a single fecal microbiota capsule in obese adolescents may reduce long-term metabolic risks, despite no significant weight loss—suggesting gut bacteria could influence future obesity treatment strategies.
Effects of vitamin D supplementation on metabolic factors, serum omentin-1, and anthropometric indices in middle-aged women with prediabetes: a double-blind randomized controlled trial
October 27, 2025 / vitamin D / insulin resistance / prediabetes treatment / metabolic health / women’s health
In prediabetic women, vitamin D supplementation significantly improved insulin secretion and resistance markers but had no effect on fasting glucose, lipid profiles, body composition, or omentin-1 levels—highlighting the need for further investigation.
GLP-1s Dominate Headlines — But Obesity Surgery Wins on Cost
October 24, 2025 / GLP-1 agonists / bariatric surgery / obesity treatment cost / metabolic health / weight loss solutions
Despite GLP-1 agonists’ popularity, metabolic and bariatric surgery remains more cost-effective long-term, offering durable outcomes at a fraction of the cumulative cost of ongoing pharmacologic obesity treatments.
Scientists question the safety and efficacy of the diet for metabolic health
October 22, 2024 / ketogenic diet / fatty liver disease / insulin resistance / metabolic health risks / blood sugar regulation
A long-term mouse study revealed that while the ketogenic diet prevents weight gain, it may cause fatty liver, impaired insulin secretion, and poor blood sugar regulation—raising concerns about its safety for sustained metabolic health.
Assessing the relationship between cardiometabolic diseases and the risk of developing aggressive prostate cancer: a systematic review and meta-analysis
October 25, 2025 / aggressive prostate cancer / cardiometabolic disease / diabetes and cancer / obesity risk / hypertension cancer link
This meta-analysis found that diabetes, obesity, and hypertension are significantly associated with increased risk of aggressive prostate cancer, highlighting the importance of cardiometabolic disease management in potentially reducing cancer progression and improving outcomes.
Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease
October 27, 2025 / GDNF therapy / obesity treatment / fatty liver disease / metabolic health / NAFLD research
Hoth Therapeutics, in partnership with the VA, has launched a study evaluating GDNF as a novel biologic targeting obesity and fatty liver disease, potentially offering dual metabolic and neurotrophic benefits for treating NAFLD and weight-related conditions.
Wegovy ushers in double-digit weight loss era, redefining metabolic disease treatment
October 23, 2025 / Wegovy weight loss / GLP-1 therapy / metabolic disease treatment / obesity diabetes link / semaglutide benefits
Wegovy (semaglutide) and other GLP-1 receptor agonists are redefining obesity and diabetes care by targeting metabolic, inflammatory, and hormonal dysfunction—ushering in a new era of double-digit weight loss and integrated metabolic disease management.
Weight-Loss Surgery Trumps Ozempic For Long-Term Health
October 23, 2025 / weight-loss surgery / GLP-1 medications / diabetes treatment / long-term obesity outcomes / metabolic health benefits
A Cleveland Clinic study shows weight-loss surgery significantly outperforms GLP-1 drugs over 10 years, offering greater weight loss, improved blood sugar control, reduced medication use, and lower risks of death, heart disease, kidney damage, and diabetic retinopathy.
Visceral-to-peripheral adiposity ratio in proneness to sarcopenic obesity: association with low muscle strength, but not low muscle mass, in young women of South Asian descent
October 24, 2024 / sarcopenic obesity / visceral fat / muscle strength / South Asian women / metabolic risk
In young South Asian women, low muscle strength—but not low muscle mass—was linked to higher visceral-to-peripheral fat ratios and adverse lipid profiles, suggesting early metabolic risk markers for developing sarcopenic obesity.
Innovent’s Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
October 26, 2025 / mazdutide trial / GLP-1 GCG dual agonist / type 2 diabetes / obesity treatment / glycemic control
In the Phase 3 DREAMS-3 trial, mazdutide, a dual GLP-1/GCG receptor agonist, demonstrated superior glycemic control and weight loss over semaglutide in Chinese patients with type 2 diabetes and obesity, with a favorable and consistent safety profile.
Early menopause increases risk of metabolic syndrome in women
October 21, 2025 / early menopause / metabolic syndrome risk / cardiovascular health / type 2 diabetes / women’s health
A large-scale study found that early natural menopause significantly increases the risk of metabolic syndrome, highlighting its role as a key clinical indicator for cardiometabolic risk and the importance of early intervention to prevent serious chronic diseases.
Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
October 21, 2025 / VK2735 trial / obesity treatment / GLP-1 GIP dual agonist / weight loss maintenance / Viking Therapeutics
Viking Therapeutics has launched a Phase 1 trial to evaluate maintenance dosing strategies for VK2735, a dual GLP-1/GIP receptor agonist, aiming to sustain weight loss in obese patients and improve long-term treatment adherence through flexible dosing options.
Scientists Discover a Molecule That Links Aging Throughout the Entire Body
October 25, 2025 / CtBP2 biomarker / biological aging / metabolic health / anti-aging therapy / longevity research
Researchers identified CtBP2 as a metabolic molecule linked to biological aging; higher blood levels correlate with better metabolic health and longevity, suggesting CtBP2 could serve as a biomarker and potential therapeutic target for age-related disease prevention.
TRF1 protein depletion linked to leaner mice and altered metabolism
October 27, 2025 / TRF1 protein / metabolic health / obesity resistance / telomere biology / energy metabolism
Depleting TRF1, a telomere-binding protein, led to leaner mice with healthier metabolic profiles and lower fat accumulation—independent of telomere shortening—revealing a novel role for TRF1 in energy regulation and obesity resistance, particularly in males.
Mechanism that aggravates metabolic fatty liver disease discovered
October 22, 2025 / fatty liver disease / E2F2 protein / liver cancer risk / bile acid metabolism / metabolic steatosis
Researchers identified E2F2 as a key driver in the progression of metabolic fatty liver disease by promoting toxic lipid buildup and impaired bile acid clearance. Targeting E2F2 may offer a new therapeutic strategy to prevent cirrhosis and liver cancer.
Understanding Metabolic Dysfunction in Indian Liver Disease
October 25, 2025 / MASLD India / fatty liver disease / metabolic dysfunction / Indian obesity trends / diabetes liver connection
Researchers emphasize the rising burden of MASLD in India, driven by obesity, diabetes, and socioeconomic factors. They call for culturally tailored interventions, early detection strategies, and further research into unique metabolic profiles across diverse Indian populations.
Bergamot leaf extract may protect the heart from damage related to obesity
October 26, 2025 / bergamot extract / obesity heart damage / cardiac remodeling / insulin resistance / natural cardioprotection
Bergamot leaf extract (BLE) improved insulin resistance, lipid levels, and reduced cardiac inflammation and fibrosis in obese rats, suggesting its potential as a cardioprotective agent against obesity-induced heart remodeling and metabolic dysfunction.
Cardiometabolic Diseases Linked to Aggressive Prostate Cancer
October 25, 2025 / aggressive prostate cancer / cardiometabolic disease / diabetes link / obesity and cancer / hypertension risk
A large meta-analysis revealed that diabetes, obesity, and hypertension significantly increase the risk of aggressive prostate cancer, underscoring the importance of managing cardiometabolic health to reduce cancer progression and improve patient outcomes.
Guggenheim upgrades Neumora Therapeutics stock to Buy on obesity data
October 27, 2025 / obesity treatment / NLRP3 inhibitor / cardiometabolic disease / GLP-1 synergy / Neumora Therapeutics
Neumora Therapeutics’ NLRP3 inhibitor program shows promising preclinical obesity data, suggesting potential synergy with GLP-1 drugs by reducing inflammation and enhancing weight loss, positioning the therapy as a novel approach to treating cardiometabolic and hepatic complications of obesity.